|Bid||324.10 x 1300|
|Ask||325.00 x 1000|
|Day's Range||319.01 - 325.82|
|52 Week Range||220.20 - 325.82|
|Beta (5Y Monthly)||0.43|
|PE Ratio (TTM)||49.71|
|Earnings Date||Apr 25, 2022 - Apr 29, 2022|
|Forward Dividend & Yield||3.92 (1.34%)|
|Ex-Dividend Date||May 13, 2022|
|1y Target Est||304.28|
Radius (RDUS) will go private following the acquisition by Gurnet Point Capital and Patient Square Capital.
Wall Street is likely poised to scale back its forecasts for profits, with ugly consequences for stocks, so investors will want to identify companies that are immune.
Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.